Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Xspray Pharma in connection with its rights issue of units
Mandate

Vinge is advising Xspray Pharma in connection with its rights issue of units

May 04, 2023 Capital Markets and Public M&A

Through the rights issue of units, Xspray is expected to receive approximately SEK 300 million, with two warrant series approximately amounting together up to an additional SEK 300 million upon full exercise.

Xspray Pharma AB (publ) is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment. The company's goal is to become a leader in the development of improved PKIs for cancer treatment. Xspray’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård Nevonen, Linnéa Sellström and Adrian Filipovic.

 

Related

Vinge has advised Stendörren Fastigheter in connection with a directed share issue of approximately SEK 300 million

 Vinge has advised the property company Stendörren Fastigheter AB (publ) in connection with a directed share issue through which the company raises proceeds of approximately SEK 300 million before transaction costs.
May 14, 2025

Vinge has advised EQT AB in connection with its bond issue in the aggregate principal amount of USD 500,000,000

 EQT AB (publ) has issued senior bonds in the aggregate principal amount of USD 500,000,000 with an interest rate of 5.850%, due 2035, at a price equal to 99.783% of the aggregate principal amount thereof.
May 13, 2025

Vinge has advised Qlik in connection with acquisition

 Vinge has advised the Qlik Group in connection with its acquisition of the Qloud Cover Migration technology from Stretch Qonnect. This automated solution, to be branded as the Qlik Analytics Migration Tool, eliminates the complexity of migrating from QlikView, Qlik Sense, and NPrinting to Qlik Cloud – a persistent barrier to cloud adoption.
May 13, 2025